TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 20)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. – 24)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Breakdown of primary sources
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. – 33)

4 PREMIUM INSIGHTS (Page No. – 37)
4.1 PROTEIN EXPRESSION MARKET OVERVIEW
4.2 NORTH AMERICA: PROTEIN EXPRESSION MARKET, BY APPLICATION & COUNTRY (2019)
4.3 PROTEIN EXPRESSION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW (Page No. – 39)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of chronic diseases
5.2.1.2 Growth in the geriatric population
5.2.1.3 Increasing demand for protein biologics
5.2.1.4 Growth in the life science and biopharmaceutical industries
5.2.1.5 Increasing research activities on recombinant-based protein expression
5.2.1.6 Availability of funding for protein-based research
5.2.2 RESTRAINTS
5.2.2.1 High cost of protein expression reagents and instruments
5.2.2.2 Increasing consolidation and high barriers for new entrants
5.2.3 OPPORTUNITIES
5.2.3.1 Emergence of microfluidics
5.2.3.2 Emerging economies offer significant growth potential
5.2.4 CHALLENGES
5.2.4.1 Contamination—A major challenge in protein purification
5.2.4.2 Complexities associated with membrane protein expression and purification
5.3 THE IMPACT OF COVID-19 OUTBREAK ON THE GROWTH OF THE PROTEIN EXPRESSION MARKET
5.3.1 VACCINE AND THERAPY DEVELOPMENT FOR COVID-19 TO BOOST THE MARKET FOR PROTEIN EXPRESSION SYSTEMS
5.3.2 INCREASING RESEARCH TO IDENTIFY IDEAL TARGET PROTEINS ON SARS-COV-2 FOR DEVELOPING THERAPIES AS WELL AS DIAGNOSTIC TESTS
5.3.3 LOGISTIC CHALLENGES DUE TO SARS-COV-2 MAY RESULT IN DELAY IN PROTEIN EXPRESSION RESEARCH
5.3.4 EFFECT OF COVID-19 ON THE PHARMACEUTICAL INDUSTRY
5.3.5 PHARMA & BIOTECH COMPANIES ARE DECREASING THEIR DEPENDENCY ON CHINA BY MOVING THEIR MANUFACTURING FACILITIES FROM CHINA TO OTHER PARTS OF THE WORLD
5.3.6 INCREASE IN GOVERNMENT FUNDING

6 PROTEIN EXPRESSION MARKET, BY SYSTEM TYPE (Page No. – 50)
6.1 INTRODUCTION
6.2 PROKARYOTIC EXPRESSION SYSTEMS
6.2.1 ESCHERICHIA COLI SYSTEMS
6.2.1.1 Increasing use of E. coli systems for the production of commercial proteins to support market growth
6.2.2 OTHER PROKARYOTIC EXPRESSION SYSTEMS
6.3 MAMMALIAN CELL EXPRESSION SYSTEMS
6.3.1 CHINESE HAMSTER OVARY SYSTEMS
6.3.1.1 Chinese hamster ovary systems account for the largest share of the mammalian expression systems market
6.3.2 OTHER MAMMALIAN CELL SYSTEMS
6.4 INSECT CELL EXPRESSION SYSTEMS
6.4.1 BACULOVIRUS SYSTEMS
6.4.1.1 Baculovirus systems show high yield and expression level, especially for intracellular proteins
6.4.2 OTHER INSECT CELL SYSTEMS
6.5 YEAST EXPRESSION SYSTEMS
6.5.1 K. LACTIS SYSTEMS
6.5.1.1 K. lactis systems held the largest share of the yeast expression systems market in 2019
6.5.2 SACCHAROMYCES SYSTEMS
6.5.2.1 Saccharomyces systems channelize the direction of foreign proteins into secretory pathways using various signals
6.5.3 PICHIA SYSTEMS
6.5.3.1 Pichia systems are used for the production of antifreeze proteins and lytic enzymes
6.5.4 OTHER YEAST EXPRESSION SYSTEMS
6.6 CELL-FREE EXPRESSION SYSTEMS
6.6.1 INCREASING DEMAND FOR RECOMBINANT PROTEINS WILL DRIVE THE GROWTH OF THIS SEGMENT
6.7 ALGAL-BASED EXPRESSION SYSTEMS
6.7.1 GROWTH IN THE VACCINES MARKET IS SUPPORTING THE GROWTH OF THIS SEGMENT

7 PROTEIN EXPRESSION MARKET, BY PRODUCT & SERVICE (Page No. – 63)
7.1 INTRODUCTION
7.2 REAGENTS
7.2.1 REAGENTS ARE THE LARGEST AND FASTEST-GROWING PRODUCTS IN THE PROTEIN EXPRESSION MARKET
7.3 EXPRESSION VECTORS
7.3.1 EXPRESSION VECTORS ARE FREQUENTLY USED DURING TRANSFECTION
7.4 COMPETENT CELLS
7.4.1 INCREASING DEMAND FOR THERAPEUTIC PROTEINS TO DRIVE MARKET GROWTH
7.5 INSTRUMENTS
7.5.1 INSTRUMENTS HELP IN THE EFFICIENT TRANSFER OF GENETIC MATERIALS INTO HOST CELLS
7.6 SERVICES
7.6.1 RISING DEMAND FOR CUSTOMIZED PROTEINS TO DRIVE THE MARKET FOR SERVICES

8 PROTEIN EXPRESSION MARKET, BY APPLICATION (Page No. – 69)
8.1 INTRODUCTION
8.2 THERAPEUTIC APPLICATIONS
8.2.1 THERAPEUTIC PROTEINS ARE USED TO TREAT PATHOLOGICAL CONDITIONS
8.3 INDUSTRIAL APPLICATIONS
8.3.1 RAPID GROWTH IN THE INDUSTRIAL ENZYMES MARKET IS AN IMPORTANT DRIVER FOR THE GROWTH OF THIS SEGMENT
8.4 RESEARCH APPLICATIONS
8.4.1 INCREASING INVESTMENTS IN RESEARCH ACTIVITIES WILL DRIVE THE GROWTH OF THIS APPLICATION SEGMENT

9 PROTEIN EXPRESSION MARKET, BY END USER (Page No. – 74)
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE THE LARGEST END USERS OF PROTEIN EXPRESSION SYSTEMS
9.3 ACADEMIC RESEARCH INSTITUTES
9.3.1 INCREASING GOVERNMENT AND PRIVATE FUNDING TO SUPPORT MARKET GROWTH
9.4 CONTRACT RESEARCH ORGANIZATIONS
9.4.1 INCREASING CLINICAL TRIALS AND OUTSOURCING OF PHARMACEUTICAL MANUFACTURING WILL DRIVE MARKET GROWTH
9.5 OTHER END USERS

10 PROTEIN EXPRESSION MARKET, BY REGION (Page No. – 79)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.1.1 The US dominates the global protein expression market
10.2.2 CANADA
10.2.2.1 Government funding for research and innovation to support market growth
10.3 EUROPE
10.3.1 GERMANY
10.3.1.1 Germany is the largest market for protein expression in Europe
10.3.2 FRANCE
10.3.2.1 Proteomics research in France is strongly supported by the government
10.3.3 UK
10.3.3.1 Surge in the prevalence of chronic diseases will drive market growth
10.3.4 ITALY
10.3.4.1 Growth in this market is driven by the increase in life sciences research projects
10.3.5 SPAIN
10.3.5.1 Spain has an established network of research centers, universities, and hospitals
10.3.6 REST OF EUROPE (ROE)
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.1.1 Growth in R&D to enhance technological capabilities in the country
10.4.2 JAPAN
10.4.2.1 Rising geriatric population to support market growth
10.4.3 INDIA
10.4.3.1 Increasing investments in proteomics research to support market growth
10.4.4 AUSTRALIA
10.4.4.1 Increasing focus of the healthcare system on precision medicine to offer significant growth opportunities in Australia
10.4.5 REST OF ASIA PACIFIC (ROAPAC)
10.5 REST OF THE WORLD (ROW)
10.5.1 LATIN AMERICA
10.5.1.1 Increasing research in the field of stem cells to support market growth in Latin America
10.5.2 MIDDLE EAST & AFRICA
10.5.2.1 Government investments in the healthcare sector and growing pharmaceuticals industry to drive market growth in the region

11 COMPETITIVE LANDSCAPE (Page No. – 127)
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS
11.3 COMPETITIVE LEADERSHIP MAPPING
11.3.1 VISIONARY LEADERS
11.3.2 INNOVATORS
11.3.3 DYNAMIC DIFFERENTIATORS
11.3.4 EMERGING COMPANIES
11.4 COMPETITIVE SCENARIO
11.4.1 KEY DEVELOPMENTS IN THE PROTEIN EXPRESSION MARKET

12 COMPANY PROFILES (Page No. – 133)
(Business overview, Products and Services offered, Recent developments, SWOT analysis, MNM view)*
12.1 THERMO FISHER SCIENTIFIC, INC.
12.2 MERCK KGAA
12.3 GENSCRIPT BIOTECH CORPORATION
12.4 AGILENT TECHNOLOGIES, INC.
12.5 TAKARA BIO, INC.
12.6 BIO-RAD LABORATORIES, INC.
12.7 LONZA
12.8 PROMEGA CORPORATION
12.9 NEW ENGLAND BIOLABS
12.11 OXFORD EXPRESSION TECHNOLOGIES LTD.
12.11 LIFESENSORS
12.12 PROTEOGENIX
12.13 SYNTHETIC GENOMICS, INC. (SGI)
12.14 PEAK PROTEINS LTD.
12.15 PROMAB BIOTECHNOLOGIES, INC.
12.16 SINO BIOLOGICAL, INC.
12.17 LUCIGEN CORPORATION.
12.18 ARTES BIOTECHNOLOGY GMBH
12.19 JENA BIOSCIENCE GMBH
12.20 BIONEER CORPORATION
12.21 LENIOBIO GMBH

*Business overview, Products and Services offered, Recent developments, SWOT analysis, MNM view might not be captured in case of unlisted companies.